Literature DB >> 33339537

Clinical characteristics and outcome of SARS-CoV-2 infection in admitted patients with chronic lymphocytic leukemia from a single European country.

Ana Muntañola1, Guillermo Villacampa2,3, José Ángel Hernández-Rivas4, Rosalía Alonso5, Fátima Mirás6, Santiago Osorio7, Mónica Baile8, Patricia Baltasar9, Javier López Jiménez10, Ines Hernandez-Rodriguez11, Susana Valenciano12, Ana Alfayate13, Eva Gimeno14, Abelardo Bárez15, Ana C Oliveira16, Rosalía Riaza17, Pilar Romero18, Julio Delgado19, Lucrecia Yáñez20, Amaya Zabalza21, Ana Torres22, Mª Isabel Gómez-Roncero23, Marta Crespo24, Raúl Córdoba25, Juan José Mateos-Mazón26, Sonia Pérez27, Rafael Andreu28, Jorge Labrador29, Mª Elena Ruiz30, César Andrés Velasquez31, Mª José Terol32, Raquel Santiago33, Mª Jesús Vidal34, Fiz Campoy García35, Lucía Villalón36, Begoña S Muiña37, Joan Alfons Soler38, Cristina Seri39, Mª José Sánchez40, Amalia Cuesta41, Rafael Ramos42, Adrián Sánchez-Montalvá24, Isabel Ruiz-Camps24, Marcos González8, Pau Abrisqueta43, Francesc Bosch24.   

Abstract

Entities:  

Year:  2020        PMID： 33339537     DOI： 10.1186/s40164-020-00195-x

Source DB:  PubMed          Journal:  Exp Hematol Oncol        ISSN： 2162-3619


× No keyword cloud information.
  2 in total

1.  Inhibition of Bruton tyrosine kinase in patients with severe COVID-19.

Authors:  Mark Roschewski; Michail S Lionakis; Jeff P Sharman; Joseph Roswarski; Andre Goy; M Andrew Monticelli; Michael Roshon; Stephen H Wrzesinski; Jigar V Desai; Marissa A Zarakas; Jacob Collen; Keith Rose; Ahmed Hamdy; Raquel Izumi; George W Wright; Kevin K Chung; Jose Baselga; Louis M Staudt; Wyndham H Wilson
Journal:  Sci Immunol       Date:  2020-06-05

2.  Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19.

Authors:  Santiago Thibaud; Douglas Tremblay; Sheena Bhalla; Brittney Zimmerman; Keith Sigel; Janice Gabrilove
Journal:  Br J Haematol       Date:  2020-06-04       Impact factor: 6.998
  2 in total
  4 in total

1.  Booster effect after SARS-CoV-2 vaccination in immunocompromised hematology patients with prior COVID-19.

Authors:  José Luis Piñana; Ramon Garcia-Sanz; Rodrigo Martino; María Garcia-Roa; Gabriel Andrés Martin-Martin; Irene Risco-Gálvez; Mar Tormo; Pilar Martinez-Barranco; Sara Marcos-Corrales; Marisa Calabuig; Venancio Conesa; Anabel Teruel; Sara Ruiz-Pérez; Carlos Solano; David Navarro; Ángel Cedillo; Anna Sureda
Journal:  Blood Adv       Date:  2022-01-08

Review 2.  The Evolving Landscape of Chronic Lymphocytic Leukemia on Diagnosis, Prognosis and Treatment.

Authors:  Claudia Pérez-Carretero; Isabel González-Gascón-Y-Marín; Ana E Rodríguez-Vicente; Miguel Quijada-Álamo; José-Ángel Hernández-Rivas; María Hernández-Sánchez; Jesús María Hernández-Rivas
Journal:  Diagnostics (Basel)       Date:  2021-05-10

Review 3.  Management of patients with chronic lymphocytic leukemia during the SARS-CoV-2 pandemic.

Authors:  Romeo Gabriel Mihaila
Journal:  Oncol Lett       Date:  2021-07-03       Impact factor: 2.967

4.  SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group.

Authors:  José Luis Piñana; Lucia López-Corral; Rodrigo Martino; Juan Montoro; Lourdes Vazquez; Ariadna Pérez; Gabriel Martin-Martin; Ana Facal-Malvar; Elena Ferrer; María-Jesús Pascual; Gabriela Sanz-Linares; Beatriz Gago; Andrés Sanchez-Salinas; Lucia Villalon; Venancio Conesa-Garcia; Maria T Olave; Javier López-Jimenez; Sara Marcos-Corrales; Marta García-Blázquez; Valentín Garcia-Gutiérrez; José Ángel Hernández-Rivas; Ana Saus; Ildefonso Espigado; Carmen Alonso; Rafael Hernani; Carlos Solano; Blanca Ferrer-Lores; Manuel Guerreiro; Montserrat Ruiz-García; Juan Luis Muñoz-Bellido; David Navarro; Angel Cedillo; Anna Sureda
Journal:  Am J Hematol       Date:  2021-11-02       Impact factor: 13.265
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.